Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MediWound's $70m IPO at low end of target

This article was originally published in Clinica

Executive Summary

Israel’s MediWound has priced its initial public offering, but the $70m total was at the low end of its expectations. The firm had been hoping to sell five million shares at $14-16 each, raising up to $80m in total, in fact had to settle for the bottom of this range. The underwriters also have the option to purchase up to 750,000 more shares at the same price, which could top up the grand total. The company began trading on the Nasdaq today under the ticker symbol MDWD. In spite of the disappointing total, the offering will be heartening to both MediWound and other start-ups considering taking a chance on the public market. So far this year, Clinica has recorded a total of 12 filings, and four, including MediWound, have succeeded in going public, bolstering hopes that the medtech IPO market is picking up.

You may also be interested in...

What are the hottest innovations from Israel?

Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.

EuroPCR: St Jude and Philips talk up rival intravascular imaging techs

St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.

EuroPCR: Medtronic's drug-coated balloon keeps rising

A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts